Talk about burying bad news on a Friday afternoon - and before a long holiday weekend, too. Johnson & Johnson has initiated yet another recall, though, and this time the withdrawn products include various types of Tylenol, Benadryl, Sudafed and Sinutab that were sold in the US, Brazil and the Caribbean. Also withdrawn was Rolaids Multi-Symptom Berry sold in the US (see this).
In making the 'let's-hope-this-gets-somewhat-ignored' announcement, J&J also issued a separate statement saying these recalls were initiated as a result of a so-called Comprehensive Action Plan that was given the FDA last summer. This was undertaken to revamp procedures at its McNeil Consumer Healthcare plant in Fort Washington, Pa., which is now closed for retooling.
The added statement is not only an attempt to forestall further regulatory action, but also convince the public that the beleaguered healthcare giant has a handle on systemic problems that have sapped customer confidence, prompted investigations, spawned shareholder lawsuits and sullied a once widely admired corporate image.
If these recalls keep up much longer, there may be few over-the-counter meds for J&J to sell.